Superpower

Building a new healthcare system. Founder @superpower Sharing my learnings: https://t.co/XnsVjvb0JI

Superpower is a San Francisco healthtech company founded in 2023 by Max Marchione, Jacob Peters and Kevin Unkrich that sells an app-based membership built around preventive care. The $199 membership covers a comprehensive annual lab test that screens for more than 100 biomarkers across cardiovascular health, hormones, metabolism, inflammation and biological age , paired with clinician access and longitudinal tracking inside the app. Superpower Peptides extends that membership into one of the most contested corners of consumer health, giving members a sanctioned channel for peptide therapies aimed at recovery, metabolic health and longevity. The launch is timed to a real regulatory inflection point. Peptides currently sit in a grey zone, with the FDA classifying BPC-157 as a Category 2 bulk drug substance with safety concerns, meaning licensed pharmacies are prohibited from compounding it for human use , which has pushed demand toward unregulated research-chemical resellers. Marchione had been telegraphing this move for months. He told Sherwood News the company was ready to roll out peptides for its patients as soon as it got the nod from the FDA, that the supply chain was set up, and that Superpower was also working with biotechs to run clinical trials on some peptides . Today's announcement turns that groundwork into a shipping product. For founders and investors tracking the category, this is a useful data point on how a membership-style preventive care brand attempts to formalize a market that has so far been dominated by anonymous vendors. Superpower is one of several startups that interprets blood tests and sells supplements , and the peptide launch is its bid to own a higher-trust position as competitors including Hims & Hers move into the same space. The interesting question now is whether tying peptide access to longitudinal biomarker data inside an existing membership produces better adherence and outcomes than the standalone telehealth model.

Tags

Comments (15)